Where does Opko Ireland Global Holdings, Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Opko Ireland Global Holdings, Ltd. ranks #12,152 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Opko Ireland Global Holdings, Ltd. hold?

Opko Ireland Global Holdings, Ltd. holds 25 US utility patents granted between 2015 and 2020, spanning 10 technology areas.

What is Opko Ireland Global Holdings, Ltd.'s Innovation Score?

Opko Ireland Global Holdings, Ltd. has an Innovation Score of 37.4 out of 100 (top 44% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Opko Ireland Global Holdings, Ltd. focus on?

Opko Ireland Global Holdings, Ltd.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 24 patents, ranking #816 of 6,058 assignees active in that subclass. Grants appear in 10 CPC subclasses total.

Is Opko Ireland Global Holdings, Ltd.'s patent grant rate increasing or decreasing?

Opko Ireland Global Holdings, Ltd.'s recent grant velocity is -96% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Opko Ireland Global Holdings, Ltd.'s patents?

Opko Ireland Global Holdings, Ltd.'s patents average 29.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Opko Ireland Global Holdings, Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Opko Ireland Global Holdings, Ltd.

USPTO PatentsView assignee record - 25 granted patents across 10 technology areas, recorded in grant years 2015–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Opko ranks #12,152 of 49,997 tracked US assignees by granted-patent volume, with 25 patents across 10 technology areas.

#12,152
of 49,997 US assignees by volume: Top 44%
by Innovation Score (37.4/100): 29.2
avg claims per patent: -96%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R12152 · Foreign Corporation #12,152 · 25 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 25 grants
UPPER-Q #12,152/49,997
PHOTO-FINISH Norma U S Holding
CPC-FOCUS A61P · 10 areas
INNOV-THIN 37.4/100
CLAIMS-DENSE 29.2 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -96% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Norma U.S. Holding LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Opko’s 37.4 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 11.3 pts (30%) Velocity 0.0 pts (0%) Breadth 11.2 pts (30%) Claim depth 15.0 pts (40%)

Qualcomm Incorporated · highest

85
Case-mate · near

37
Cedes · near

37
Diebold · near

37
Opko Ireland Global… · this assignee

37
VirnetX · near

37
3D Lighting… · lowest

7

What this shows Opko's Innovation Score is 37.4/100 (top 44% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Opko?

Each dot is one of Opko’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Opko’s own 29.2 claims/patent is ABOVE the 17.9 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Opko vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Opko's grants concentrate

Opko Ireland Global Holdings, Ltd. is a focused PatentsView assignee: 10 CPC subclasses with 96% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2016 (7 grants) versus a trough of 1 in 2020. By volume, Opko sits between Norma U.S. Holding LLC and Oetiker Schweiz AG.

Norma U S Holding

25
Nuvaira

25
OBI Pharma

25
OBP Medical

25
Optimizely

25
OPW Fueling Compo…

25
Obalon Therapeuti…

25
Oetiker Schweiz

25
Opko Ireland Glob… ◀

25

What this shows Opko holds 25 patents at rank #12,146, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Opko

By rank, the assignees closest to #12,146 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Opko's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Opko, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Opko ranks #816 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (37 here).

Cedes AG 37 VirnetX, Inc. 37 Diebold, Inc. 37 Case-mate, Inc. 37

Opko's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 44% higher than 56% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Opko Ireland Global Holdings, Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	8.0%
2016	7	28.0%
2017	2	8.0%
2018	6	24.0%
2019	7	28.0%
2020	1	4.0%

Which technologies does Opko Ireland Global Holdings, Ltd. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 24

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 24

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

C07K - Peptides 3

C01G - Compounds Containing Metals NOT Covered BY Subclasses C01d OR C01f 3

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

C01F - Compounds OF THE Metals Beryllium, Magnesium, Aluminium, Calcium, Strontium, Barium, Radium, Thorium, OR OF THE Rare-earth Metals 2

C01P - Indexing Scheme Relating TO Structural AND Physical Aspects OF Solid Inorganic Compounds 2

C07C - Acyclic OR Carbocyclic Compounds 1

B82Y - Specific Uses OR Applications OF NANOSTRUCTURES; Measurement OR Analysis OF NANOSTRUCTURES; Manufacture OR Treatment OF Nanostructures 1

Top 10 of 10 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Opko Ireland Global Holdings, Ltd.'s patent record in context - here's where to go next.

Opko Ireland Global Holdings, Ltd.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 96% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #12,152 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Opko Ireland Global Holdings, Ltd. against Norma U.S. Holding LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.